Psyence Biomedical makes $3.5M follow-on investment in PsyLabs

Psyence Biomedical (PBM) made a $3,500,000 follow-on investment in PsyLabs, a producer of purified psychedelic active pharmaceutical ingredients. This investment solidifies PsyLabs’ position as a primary supplier of high-quality, GMP-grade psychedelic compounds, including psilocybin and ibogaine, for Psyence BioMed’s clinical research programs. The enhanced collaboration ensures Psyence BioMed continues to have access to an ethical, sustainable, and reliable supply of premium psychedelic compounds to advance its clinical pipeline. This investment made on August 15th, 2025, follows-on from the previously made USD$500,000 investment in PsyLabs in April 2025.